Skip to main content
Top
Published in: Medical Oncology 2/2011

01-06-2011 | Original Paper

Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population

Authors: Yun-Sheng Hu, Yong Pan, Wen-Hai Li, Yong Zhang, Jun Li, Bao-An Ma

Published in: Medical Oncology | Issue 2/2011

Login to get access

Abstract

The TGF-beta signaling pathway is important in the development and invasion of cancers. Int7G24A is an intronic variant of TGF-beta receptor type 1 and has been shown to be associated with the occurrence of some kinds of cancers. Nevertheless, the association of this polymorphism with osteosarcoma is unknown. In this study, we evaluated Int7G24A variant frequencies in osteosarcoma cases. The case–control study involved 168 osteosarcoma patients and 168 age- and gender-matched controls. The blood samples were obtained, and Int7G24A variant was determined by PCR amplification and DNA sequencing. The odds ratio (OR) and 95% confidence interval (95% CI) for the Int7G24A polymorphism were calculated using unconditional logistic regression adjusted for age and gender. Three analysis models, which are the dominant model, additive model and recessive model, were used to analyze the contribution of Int7G24A variant to osteosarcoma susceptibility. Heterozygotic and homozygotic Int7G24A variants were 33.93 and 6.55% in total 168 cases, while they were 28.57 and 2.98%, respectively, in total 168 controls. The ORs for homozygosity and heterozygosity of Int7G24A allele were 1.56 [95% CI, 0.98–1.83] and 2.89 [95% CI, 1.46–4.92] in additive model. The ORs of Int7G24A genotypes in dominant model and in recessive model were 1.75 [95% CI, 1.21–2.68] and 2.21 [95% CI, 1.34–4.72], respectively. There were significant increases in Int7G24A variants in osteosarcoma cases when compared to control in every three models. Further analysis showed that Int7G24A genotypes were not associated with gender and osteosarcoma location of the cases. However, Int7G24A was significantly increased in the cases less than 20 years old. Moreover, Int7G24A was significantly associated with increased distant metastasis of osteosarcoma. It is concluded that Int7G24A is a polymorphism of TGFBR1 that is associated with the susceptibility and distant metastasis of osteosarcoma.
Literature
2.
go back to reference Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg. 2009;17:515–27.PubMed Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg. 2009;17:515–27.PubMed
3.
go back to reference McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12:925–30.PubMed McIntyre JF, Smith-Sorensen B, Friend SH, Kassell J, Borresen AL, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994;12:925–30.PubMed
5.
go back to reference Neil JR, Galliher AJ, Schiemann WP. Tgf-beta in cancer and other diseases. Future Oncol. 2006;2:185–9.PubMedCrossRef Neil JR, Galliher AJ, Schiemann WP. Tgf-beta in cancer and other diseases. Future Oncol. 2006;2:185–9.PubMedCrossRef
6.
go back to reference Podar K, Raje N, Anderson KC. Inhibition of the tgf-beta signaling pathway in tumor cells. Recent Results Cancer Res. 2007;172:77–97.PubMedCrossRef Podar K, Raje N, Anderson KC. Inhibition of the tgf-beta signaling pathway in tumor cells. Recent Results Cancer Res. 2007;172:77–97.PubMedCrossRef
7.
go back to reference Mioh H, Chen JK. Differential inhibitory effects of tgf-beta on egf-, pdgf-, and hbgf-1-stimulated mg63 human osteosarcoma cell growth: possible involvement of growth factor interactions at the receptor and postreceptor levels. J Cell Physiol. 1989;139:509–16.PubMedCrossRef Mioh H, Chen JK. Differential inhibitory effects of tgf-beta on egf-, pdgf-, and hbgf-1-stimulated mg63 human osteosarcoma cell growth: possible involvement of growth factor interactions at the receptor and postreceptor levels. J Cell Physiol. 1989;139:509–16.PubMedCrossRef
8.
go back to reference Seitz PK, Zhu BT, Cooper CW. Effect of transforming growth factor beta on parathyroid hormone receptor binding and camp formation in rat osteosarcoma cells. J Bone Miner Res. 1992;7:541–6.PubMedCrossRef Seitz PK, Zhu BT, Cooper CW. Effect of transforming growth factor beta on parathyroid hormone receptor binding and camp formation in rat osteosarcoma cells. J Bone Miner Res. 1992;7:541–6.PubMedCrossRef
9.
go back to reference Pontbriant CM, Chen JK, Orlando JA. Tgf-beta inhibits the platelet-derived growth factor-induced formation of inositol trisphosphate in mg-63 human osteosarcoma cells. J Cell Physiol. 1990;145:488–95.PubMedCrossRef Pontbriant CM, Chen JK, Orlando JA. Tgf-beta inhibits the platelet-derived growth factor-induced formation of inositol trisphosphate in mg-63 human osteosarcoma cells. J Cell Physiol. 1990;145:488–95.PubMedCrossRef
10.
go back to reference Derynck R, Feng XH. Tgf-beta receptor signaling. Biochim Biophys Acta. 1997;1333:F105–50.PubMed Derynck R, Feng XH. Tgf-beta receptor signaling. Biochim Biophys Acta. 1997;1333:F105–50.PubMed
11.
12.
go back to reference Chen T, Jackson CR, Link A, Markey MP, Colligan BM, et al. Int7g24a variant of transforming growth factor-beta receptor type i is associated with invasive breast cancer. Clin Cancer Res. 2006;12:392–7.PubMedCrossRef Chen T, Jackson CR, Link A, Markey MP, Colligan BM, et al. Int7g24a variant of transforming growth factor-beta receptor type i is associated with invasive breast cancer. Clin Cancer Res. 2006;12:392–7.PubMedCrossRef
13.
go back to reference Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol. 2007;8:61–73.PubMedCrossRef Rosman DS, Kaklamani V, Pasche B. New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol. 2007;8:61–73.PubMedCrossRef
14.
go back to reference Song B, Margolin S, Skoglund J, Zhou X, Rantala J, et al. Tgfbr1(*)6a and int7g24a variants of transforming growth factor-beta receptor 1 in swedish familial and sporadic breast cancer. Br J Cancer. 2007;97:1175–9.PubMedCrossRef Song B, Margolin S, Skoglund J, Zhou X, Rantala J, et al. Tgfbr1(*)6a and int7g24a variants of transforming growth factor-beta receptor 1 in swedish familial and sporadic breast cancer. Br J Cancer. 2007;97:1175–9.PubMedCrossRef
15.
go back to reference Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, et al. Tgfbr1*6a and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol. 2003;21:3236–43.PubMedCrossRef Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, et al. Tgfbr1*6a and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol. 2003;21:3236–43.PubMedCrossRef
16.
go back to reference Chen T, Jackson C, Costello B, Singer N, Colligan B, et al. An intronic variant of the tgfbr1 gene is associated with carcinomas of the kidney and bladder. Int J Cancer. 2004;112:420–5.PubMedCrossRef Chen T, Jackson C, Costello B, Singer N, Colligan B, et al. An intronic variant of the tgfbr1 gene is associated with carcinomas of the kidney and bladder. Int J Cancer. 2004;112:420–5.PubMedCrossRef
17.
go back to reference Zhang HT. Int7g24a variant of the tgfbr1 gene and cancer risk: a meta-analysis of three case-control studies. Lung Cancer. 2005;49:419–20.PubMedCrossRef Zhang HT. Int7g24a variant of the tgfbr1 gene and cancer risk: a meta-analysis of three case-control studies. Lung Cancer. 2005;49:419–20.PubMedCrossRef
18.
go back to reference Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer. 1988;57:594–600.PubMedCrossRef Roberts AB, Thompson NL, Heine U, Flanders C, Sporn MB. Transforming growth factor-beta: possible roles in carcinogenesis. Br J Cancer. 1988;57:594–600.PubMedCrossRef
19.
go back to reference Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog. 1993;4:493–540.PubMed Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis. Crit Rev Oncog. 1993;4:493–540.PubMed
20.
go back to reference Miyajima A, Asano T, Seta K, Asano T, Kakoi N, et al. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology. 2003;61:1072–7.PubMedCrossRef Miyajima A, Asano T, Seta K, Asano T, Kakoi N, et al. Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma. Urology. 2003;61:1072–7.PubMedCrossRef
21.
go back to reference Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Expression of transforming growth factor-beta (tgf-beta) receptors, tgf-beta 1 and tgf-beta 2 production and autocrine growth control in osteosarcoma cells. Int J Cancer. 1994;58:440–5.PubMedCrossRef Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Expression of transforming growth factor-beta (tgf-beta) receptors, tgf-beta 1 and tgf-beta 2 production and autocrine growth control in osteosarcoma cells. Int J Cancer. 1994;58:440–5.PubMedCrossRef
22.
go back to reference Noda M, Rodan GA. Type beta transforming growth factor (tgf beta) regulation of alkaline phosphatase expression and other phenotype-related mrnas in osteoblastic rat osteosarcoma cells. J Cell Physiol. 1987;133:426–37.PubMedCrossRef Noda M, Rodan GA. Type beta transforming growth factor (tgf beta) regulation of alkaline phosphatase expression and other phenotype-related mrnas in osteoblastic rat osteosarcoma cells. J Cell Physiol. 1987;133:426–37.PubMedCrossRef
Metadata
Title
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population
Authors
Yun-Sheng Hu
Yong Pan
Wen-Hai Li
Yong Zhang
Jun Li
Bao-An Ma
Publication date
01-06-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9483-6

Other articles of this Issue 2/2011

Medical Oncology 2/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.